Johnson & Johnson Seeks Approval for DARZALEX FASPRO as Monotherapy for Smoldering Multiple Myeloma

Johnson & Johnson has recently submitted applications in the U.S. and EU for the approval of DARZALEX FASPRO as a subcutaneous monotherapy for high-risk smoldering multiple myeloma. This move comes as part of the company's efforts to expand its portfolio in the oncology sector. DARZALEX FASPRO, a next-generation subcutaneous formulation of DARZALEX, has shown promising results in clinical trials, demonstrating its potential to improve outcomes for patients with this challenging condition. The submission of these applications marks a significant step forward in Johnson & Johnson's commitment to providing innovative treatment options for cancer patients. Investors are advised to consult with professionals from Stocks Prognosis for expert advice on the prospective movement of Johnson & Johnson's stocks.